Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

Delayed Quote. Delayed  - 08/30 10:00:00 pm
2.76 USD   +1.85%
08/19 IMMUNOMEDICS : Announces conference call and webcast for fourth quar..
08/19 IMMUNOMEDICS : Preclinical Study on Enhancing Sacituzumab Govitecan ..
08/18 Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) A..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
08/19 IMMUNOMEDICS : Announces conference call and webcast for fourth quarter and fisc..
08/19 IMMUNOMEDICS : Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) A..
08/18 IMMUNOMEDICS : Management's Discussion and Analysis of Financial Condition and R..
08/18 Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in S..
08/17 IMMUNOMEDICS : reports 4Q loss
08/17 IMMUNOMEDICS INC : Results of Operations and Financial Condition, Financial Stat..
08/17 Immunomedics Announces Fiscal 2016 Results and Clinical Program Developments
08/11 Immunomedics Announces Conference Call And Webcast For Fourth Quarter And Fis..
08/08 IMMUNOMEDICS, INC. : DEADLINE TODAY: Khang & Khang LLP Announces Securities Clas..
08/08 IMMUNOMEDICS, INC. : FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Re..
More news
Sector news : Biotechnology & Medical Research - NEC
08/30DJFDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30DJNOVARTIS : FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
08/18 Immunomedics Company Presentation July 2016 - Slide Show
08/17 Immunomedics' (IMMU) CEO Cynthia Sullivan on Q4 2016 Results - Earnings Call ..
08/17 Immunomedics misses by $0.06, misses on revenue
07/07 EVOLUTION OF CANCER THERAPY : The Missing Linker
06/28 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2017 12,8 M
EBIT 2017 -42,1 M
Net income 2017 -47,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 20,4x
Capi. / Sales 2018 9,57x
Capitalization 260 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,00 $
Spread / Average Target 85%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.-11.73%260
INCYTE CORPORATION-25.01%15 290
CELLTRION, INC.--.--%11 038
LONZA GROUP AG14.78%10 080
QUINTILES TRANSNATIONA..12.76%9 173
ALKERMES PLC-43.98%6 740
More Results